The Correlation Of New Serological Markers With The Disease Phenotype And Activation In Inflammatory Bowel Diseases

Abstract

Background: The aim of the study is to assess the correlation of a new antibody panel that is developed against glycans on Crohn's disease (CD) and ulcerative colitis (UC) differentiative diagnosis and disease properties.

Methods: In the study, 137 CH and 122 UC patients and 90 controls were included. Anti- Saccharomyces cerevisiae IgG (ASCA), anti-laminaribioside IgG (ALCA), anti-chitobioside IgA (ACCA), and anti-mannobioside IgG (AMCA) were tested in serum.

Results: In 89% of ASCA positive cases in patients with CD, it was found that while minimum 1 of 77% of ASCA negative patients was positive. Positivity ratio for a single anticarbohydrate was ALCA 18 (22%), ACCA 5 (12%), and AMCA 16 (23%). A significant correlation was found between ASCA positivity (p <0.001) in operated patients and between ASCA, ALCA, and ACCA positivity (p <0.05) in patients with stricturing and fistulizing Crohn’s Disease. A significant correlation was found between ASCA, ALCA, and ACCA positivity and high serum antibody levels and disease activation (p <0.05).

Conclusion: ASCA, ALCA, and ACCA were found to be correlated with the disease complication and activation in CD. ASCA and ALCA were determined as the best markers in the differentiation between CD and UC.